119 related articles for article (PubMed ID: 31392907)
1. Management of HCV patients in cases of direct-acting antiviral failure.
Hayes CN; Imamura M; Chayama K
Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):839-848. PubMed ID: 31392907
[No Abstract] [Full Text] [Related]
2. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Voaklander R; Jacobson IM
Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):789-795. PubMed ID: 28673106
[TBL] [Abstract][Full Text] [Related]
3. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2019 Jan; 91(1):102-106. PubMed ID: 30091810
[TBL] [Abstract][Full Text] [Related]
4. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
Vermehren J; Park JS; Jacobson IM; Zeuzem S
J Hepatol; 2018 Nov; 69(5):1178-1187. PubMed ID: 30006068
[TBL] [Abstract][Full Text] [Related]
5. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
Weisberg IS; Jacobson IM
Expert Opin Pharmacother; 2017 Apr; 18(5):535-543. PubMed ID: 28092171
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
Miller MM
Am J Health Syst Pharm; 2017 Jul; 74(14):1045-1052. PubMed ID: 28687550
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Cory TJ; Mu Y; Gong Y; Kodidela S; Kumar S
Expert Opin Pharmacother; 2018 May; 19(7):749-757. PubMed ID: 29634360
[TBL] [Abstract][Full Text] [Related]
9. Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C.
Childs-Kean LM; Brumwell NA; Lodl EF
Infect Drug Resist; 2019; 12():2259-2268. PubMed ID: 31413603
[TBL] [Abstract][Full Text] [Related]
10. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
Chayama K; Hayes CN
Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
[TBL] [Abstract][Full Text] [Related]
11. Treating HCV Infection: It Doesn't Get Much Better Than This.
Naggie S
Top Antivir Med; 2019 Jan; 26(4):104-108. PubMed ID: 30641483
[TBL] [Abstract][Full Text] [Related]
12. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
Hézode C; Chevaliez S; Scoazec G; Soulier A; Varaut A; Bouvier-Alias M; Ruiz I; Roudot-Thoraval F; Mallat A; Féray C; Pawlotsky JM
Hepatology; 2016 Jun; 63(6):1809-16. PubMed ID: 26853230
[TBL] [Abstract][Full Text] [Related]
13. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
Gao LH; Nie QH; Zhao XT
Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus resistance to the new direct-acting antivirals.
Esposito I; Trinks J; Soriano V
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
[TBL] [Abstract][Full Text] [Related]
17. Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.
Suda G; Kimura M; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Kawagishi N; Nakai M; Sho T; Maehara O; Shimazaki T; Morikawa K; Natsuizaka M; Ogawa K; Sakamoto N
Hepatol Res; 2019 Nov; 49(11):1275-1285. PubMed ID: 31261439
[TBL] [Abstract][Full Text] [Related]
18. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
[TBL] [Abstract][Full Text] [Related]
19. Managing hepatitis C therapy failures and chronic kidney disease.
Fabrizi F; Messa P
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1135-1142. PubMed ID: 30309263
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
